Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (331-340 of 713) with videos related to

Pageof 72
Sort By:
Seminars in Oncology|May 3, 2008
Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemiaFrancis J Giles, Daniel J DeAngelo, Michele Baccarani, et al.
Antimicrobial Stewardship & Healthcare Epidemiology : ASHE|December 29, 2023
Antifungal stewardship: the Latin American experienceFernando Riera, Jorge Cortes Luna, Ricardo Rabagliatti, et al.
Cancer|July 29, 2010
Current patient management of chronic myeloid leukemia in Latin America: a study by the Latin American Leukemia Net (LALNET)Jorge Cortes, Carmino De Souza, Manuel Ayala-Sanchez, et al.
Cancer|June 19, 2009
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R)Hagop Kantarjian, Ricardo Pasquini, Vincent Lévy, et al.
Leukemia & Lymphoma|May 25, 2019
Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapyPrajwal Boddu, Preetesh Jain, Gautam Borthakur, et al.
Cancer|December 18, 2008
Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimensDushyant Verma, Susan O'Brien, Deborah Thomas, et al.
Leukemia Research|August 22, 2008
Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemiaChen-Hsiung Yeh, Richard Tseng, Zhong Zhang, et al.
Leukemia & Lymphoma|August 15, 2014
Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxideAlireza Eghtedar, Ildefonso Rodriguez, Hagop Kantarjian, et al.
Journal of Health Care for the Poor and Underserved|August 18, 2025
A Report on Georgia Cancer Disparities and an Economic Evaluation of a Statewide Cancer Clinicians and Scholars' ProgramJon A Hoin, Kylie Brown, Joseph Lipscomb, et al.
British Journal of Haematology|June 18, 2010
Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemiaFabio P S Santos, Hagop Kantarjian, Carmen Fava, et al.
Pageof 72

Showing results (331-340 of 713) with videos related to

Sort By:
Pageof 72
Seminars in Oncology|May 3, 2008
Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemiaFrancis J Giles, Daniel J DeAngelo, Michele Baccarani, et al.
Antimicrobial Stewardship & Healthcare Epidemiology : ASHE|December 29, 2023
Antifungal stewardship: the Latin American experienceFernando Riera, Jorge Cortes Luna, Ricardo Rabagliatti, et al.
Cancer|July 29, 2010
Current patient management of chronic myeloid leukemia in Latin America: a study by the Latin American Leukemia Net (LALNET)Jorge Cortes, Carmino De Souza, Manuel Ayala-Sanchez, et al.
Cancer|June 19, 2009
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R)Hagop Kantarjian, Ricardo Pasquini, Vincent Lévy, et al.
Leukemia & Lymphoma|May 25, 2019
Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapyPrajwal Boddu, Preetesh Jain, Gautam Borthakur, et al.
Cancer|December 18, 2008
Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimensDushyant Verma, Susan O'Brien, Deborah Thomas, et al.
Leukemia Research|August 22, 2008
Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemiaChen-Hsiung Yeh, Richard Tseng, Zhong Zhang, et al.
Leukemia & Lymphoma|August 15, 2014
Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxideAlireza Eghtedar, Ildefonso Rodriguez, Hagop Kantarjian, et al.
Journal of Health Care for the Poor and Underserved|August 18, 2025
A Report on Georgia Cancer Disparities and an Economic Evaluation of a Statewide Cancer Clinicians and Scholars' ProgramJon A Hoin, Kylie Brown, Joseph Lipscomb, et al.
British Journal of Haematology|June 18, 2010
Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemiaFabio P S Santos, Hagop Kantarjian, Carmen Fava, et al.
Pageof 72